The study compares a topical, skin-applied CPP formulation of semaglutide, a GLP-1 analogue representative of GLP/GIP-based therapies, against injectable semaglutide and untreated controls in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results